Postexposure prophylaxis for HIV following sexual exposure

Barber, Tristan; Benn, Paul

doi:10.1097/coh.0b013e32833a5e6c

Cited by 9 publications

(7 citation statements)

References 22 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,28–36 The rationale for providing PEP in these cases is no different from that for providing prophylaxis for occupational exposures. Clinicians should evaluate the circumstances of each exposure, provide counseling about the risks for infection and secondary transmission, and provide up-to-date information about the potential risks and benefits of antiretroviral chemotherapy.…”

Section: Assessment Of the Need For Occupational And Non Occupationalmentioning

confidence: 99%

Prevention of Human Immunodeficiency Virus and AIDS

Beekmann

Henderson

2014

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

Section: Assessment Of the Need For Occupational And Non Occupationalmentioning

confidence: 99%

Prevention of Human Immunodeficiency Virus and AIDS

Beekmann

Henderson

2014

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

“…Trials to evaluate maraviroc as part of PEP are planned [135]. There has been only one reported case of maraviroc as part of occupational PEP, a medical student stuck with a needle from a heavily treatment experienced HIV-infected man [136].…”

Section: Potential Usesmentioning

confidence: 99%

Clinical use of CCR5 inhibitors in HIV and beyond

2011

View full text Add to dashboard Cite

Since the discovery of CCR5 as a coreceptor for HIV entry, there has been interest in blockade of the receptor for treatment and prevention of HIV infection. Although several CCR5 antagonists have been evaluated in clinical trials, only maraviroc has been approved for clinical use in the treatment of HIV-infected patients. The efficacy, safety and resistance profile of CCR5 antagonists with a focus on maraviroc are reviewed here along with their usage in special and emerging clinical situations. Despite being approved for use since 2007, the optimal use of maraviroc has yet to be well-defined in HIV and potentially in other diseases. Maraviroc and other CCR5 antagonists have the potential for use in a variety of other clinical situations such as the prevention of HIV transmission, intensification of HIV treatment and prevention of rejection in organ transplantation. The use of CCR5 antagonists may be potentiated by other agents such as rapamycin which downregulate CCR5 receptors thus decreasing CCR5 density. There may even be a role for their use in combination with other entry inhibitors. However, clinical use of CCR5 antagonists may have negative consequences in diseases such as West Nile and Tick-borne encephalitis virus infections. In summary, CCR5 antagonists have great therapeutic potential in the treatment and prevention of HIV as well as future use in novel situations such as organ transplantation. Their optimal use either alone or in combination with other agents will be defined by further investigation.

show abstract

“…Second, recent findings demonstrate that antiretroviral treatment of infected individuals leads to significant reduced risk of transmission of the virus to their sexual partners (National Institute of Allergy and Infectious Diseases, 2011). Third, post-exposure prophylaxis against HIV by using ART (Barber & Benn, 2010) provides an important prevention tool that has high relevance for women, including women rape survivors. Fourth, a number of efficacious individual and couples behavioral HIV prevention interventions for women are now available (Diffusion of Effective Behavioral Interventions, 2011), although in the United States, many of these initiatives still do not adequately address the role of gender and power.…”

Section: Current and Future Directionsmentioning

confidence: 99%